Novo Nordisk says sales of its weight-loss medicine Wegovy exceed expectations following a January launch, boosting the company’s outlook and supporting its share price. Multiple outlets report that the results come as competition in the anti-obesity drug market intensifies, particularly against Eli Lilly’s Mounjaro. Coverage characterizes the period as a direct battle for market share among major manufacturers of GLP-1-based weight management treatments. The reports note that the January launch is the key catalyst for the current performance, with demand strong enough to push sales past forecasts. While the articles focus on the positive momentum for Novo Nordisk, they also situate the development within a broader competitive landscape where companies are racing to win prescribing and patient uptake. Overall, the information presented centers on Wegovy’s early sales performance and the intensified rivalry between Novo Nordisk and Eli Lilly in the market for weight loss drugs.